Mr. Atwood co-founded Versant Ventures, a leading healthcare-focused venture capital firm, where he serves as a Managing Director. He also has more than 15 years of operating experience in the biotechnology industry. Prior to launching his career in venture capital, Mr. Atwood was Founder, President and Chief Executive Officer of Glycomed, a publicly traded biotechnology company. Mr. Atwood also currently serves as a Board member at the private companies Veracyte, Inc., OpGen, Inc., PhaseRx, Inc., Immune Design Corp., Groove BioPharma Corp., and Spark Diagnostics, as well as the public companies, Cadence Pharmaceuticals, Inc. (CADX), Clovis Oncology, Inc. (CLVS).
Mr. Atwood received a BS in Biological Sciences from the University of California, Irvine, an MS in Ecology from the University of California, Davis, and an MBA from Harvard Business School.